ES2186717T3 - Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc. - Google Patents

Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc.

Info

Publication number
ES2186717T3
ES2186717T3 ES95915611T ES95915611T ES2186717T3 ES 2186717 T3 ES2186717 T3 ES 2186717T3 ES 95915611 T ES95915611 T ES 95915611T ES 95915611 T ES95915611 T ES 95915611T ES 2186717 T3 ES2186717 T3 ES 2186717T3
Authority
ES
Spain
Prior art keywords
peptides
class
ctl
activity
cyto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95915611T
Other languages
English (en)
Inventor
Carol Clayberger
Alan M Krensky
Peter Parham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES2186717T3 publication Critical patent/ES2186717T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE USAN FRAGMENTOS DE LOS DOMINIOS POLIMORFICOS DE LOS DOMINIOS DEL ANTIGENO DE CLASE I HLA PARA MODULAR LA ACTIVIDAD DE CELULAT. LOS PEPTIDOS SON DESDE EL {AL}1 O {AL}2- DOMINANTES, PARTICULARMENTE DE LOS ANTIGENOS HLA-A, COMPUESTOS B. LOS PEPTIDOS PUEDEN SER CONJUGADOS CON OTROS COMPUESTOS PARA SER USADOS EN DIAGNOSTICO Y TERAPIA.LOS PEPTIDOS PUEDEN BLOQUEAR LA LISIS, LA PROLIFERACION DE CTL O TIENEN OTROS EFECTOS REGULADORES.
ES95915611T 1994-04-05 1995-04-05 Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc. Expired - Lifetime ES2186717T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/222,851 US5723128A (en) 1987-01-30 1994-04-05 Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides

Publications (1)

Publication Number Publication Date
ES2186717T3 true ES2186717T3 (es) 2003-05-16

Family

ID=22833972

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95915611T Expired - Lifetime ES2186717T3 (es) 1994-04-05 1995-04-05 Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc.

Country Status (8)

Country Link
US (1) US5723128A (es)
EP (1) EP0753005B1 (es)
JP (1) JPH10501791A (es)
AT (1) ATE231884T1 (es)
CA (1) CA2187193A1 (es)
DE (1) DE69529515T2 (es)
ES (1) ES2186717T3 (es)
WO (1) WO1995026979A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011834B1 (en) * 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US6162434A (en) * 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US6436903B1 (en) * 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
CN1216900C (zh) * 1997-04-11 2005-08-31 桑斯塔特医学有限公司 用于调节免疫系统活性和抑制炎症的细胞调节性亲脂肽
US7109170B2 (en) * 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
AU2003286611A1 (en) * 2002-10-24 2004-05-13 Sangstat Medical Corporation Cytomodulating peptides and methods for treating neurological disorders
US7498309B2 (en) * 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
WO2006031226A1 (en) * 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
EP1982992B1 (en) 2006-02-07 2010-10-27 NEC Corporation Hla-binding peptide, precursor thereof, dna fragment encoding the same and recombinant vector
JPWO2008044567A1 (ja) 2006-10-12 2010-02-12 日本電気株式会社 Hla結合性ペプチド、その前駆体、それをコードするdna断片および組み換えベクター
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
WO1988005784A1 (en) * 1987-01-30 1988-08-11 The Board Of Trustees Of The Leland Stanford Junio Lymphocyte inhibition by hla peptides
WO1989007448A1 (en) * 1988-02-12 1989-08-24 Regents Of The University Of California Use of synthetic peptides to generate and manipulate cellular immunity
DE68928183T2 (de) * 1989-03-03 1998-01-08 Univ California Klasse i-mhc-modulation von oberflächenrezeptoraktivität
US5073540A (en) * 1989-05-15 1991-12-17 Receptron Composite binding site drugs
EP0540997A1 (en) * 1991-11-05 1993-05-12 F. Hoffmann-La Roche Ag Methods and reagents for HLA class I DNA typing

Also Published As

Publication number Publication date
US5723128A (en) 1998-03-03
JPH10501791A (ja) 1998-02-17
WO1995026979A1 (en) 1995-10-12
EP0753005A4 (en) 1997-06-18
DE69529515D1 (de) 2003-03-06
EP0753005B1 (en) 2003-01-29
ATE231884T1 (de) 2003-02-15
CA2187193A1 (en) 1995-10-12
EP0753005A1 (en) 1997-01-15
DE69529515T2 (de) 2003-06-12

Similar Documents

Publication Publication Date Title
ES2150949T3 (es) Regulacion de la actividad de linfocitos con la ayuda de peptidos hla.
ES2186717T3 (es) Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc.
DK549188A (da) Lymfocythaemmende hla-peptider
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
DK0935607T3 (da) Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf
ES2111027T3 (es) Aparato para aplicar sujetadores quirurgicos.
DK240090D0 (da) Dna og anvendelse deraf
DE69329344T2 (de) Spezifische modulationen des immunsystems
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
Storkus et al. Peptide-induced modulation of target cell sensitivity to natural killing.
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
DE59807369D1 (de) Medizinische Bandage
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
NO943967L (no) Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
DE69431531D1 (de) Immortalisierte menschliche fötale osteoblastenzellen
ATE139259T1 (de) Selbstantigen der primären lebercirrhose
ATE204018T1 (de) Zellwachstumsinhibitoren
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
SU888095A1 (ru) Регулируемый источник посто нного тока
ITMI930361U1 (it) Apparecchiatura per la terapia della bulimita' e dell'obesita'